BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 12399430)

  • 1. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade.
    Gómez R; Simón C; Remohí J; Pellicer A
    Endocrinology; 2002 Nov; 143(11):4339-48. PubMed ID: 12399430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability.
    Gómez R; Simón C; Remohí J; Pellicer A
    Biol Reprod; 2003 Jun; 68(6):2164-71. PubMed ID: 12606463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and rec-LH.
    van de Lagemaat R; Raafs BC; van Koppen C; Timmers CM; Mulders SM; Hanssen RG
    Endocrinology; 2011 Nov; 152(11):4350-7. PubMed ID: 21896671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model.
    Gomez R; Gonzalez-Izquierdo M; Zimmermann RC; Novella-Maestre E; Alonso-Muriel I; Sanchez-Criado J; Remohi J; Simon C; Pellicer A
    Endocrinology; 2006 Nov; 147(11):5400-11. PubMed ID: 16901966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor.
    Wang TH; Horng SG; Chang CL; Wu HM; Tsai YJ; Wang HS; Soong YK
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3300-8. PubMed ID: 12107240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model.
    Cenksoy C; Cenksoy PO; Erdem O; Sancak B; Gursoy R
    Eur J Obstet Gynecol Reprod Biol; 2014 Mar; 174():86-90. PubMed ID: 24405730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor production in growing pig antral follicles.
    Barboni B; Turriani M; Galeati G; Spinaci M; Bacci ML; Forni M; Mattioli M
    Biol Reprod; 2000 Sep; 63(3):858-64. PubMed ID: 10952932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome.
    Neulen J; Yan Z; Raczek S; Weindel K; Keck C; Weich HA; Marmé D; Breckwoldt M
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1967-71. PubMed ID: 7775647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome.
    Soares SR; Gómez R; Simón C; García-Velasco JA; Pellicer A
    Hum Reprod Update; 2008; 14(4):321-33. PubMed ID: 18385260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
    Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
    Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gonadotropin-releasing hormone agonist administration reduced vascular endothelial growth factor (VEGF), VEGF receptors, and vascular permeability of the ovaries of hyperstimulated rats.
    Kitajima Y; Endo T; Manase K; Nishikawa A; Shibuya M; Kudo R
    Fertil Steril; 2004 Mar; 81 Suppl 1():842-9. PubMed ID: 15019818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome.
    Rizk B; Aboulghar M; Smitz J; Ron-El R
    Hum Reprod Update; 1997; 3(3):255-66. PubMed ID: 9322101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential hormonal regulation of vascular endothelial growth factors VEGF, VEGF-B, and VEGF-C messenger ribonucleic acid levels in cultured human granulosa-luteal cells.
    Laitinen M; Ristimäki A; Honkasalo M; Narko K; Paavonen K; Ritvos O
    Endocrinology; 1997 Nov; 138(11):4748-56. PubMed ID: 9348202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of low-dose LH induces ovulation and prevents vascular hyperpermeability and vascular endothelial growth factor expression in superovulated rats.
    Gómez R; Lima I; Simón C; Pellicer A
    Reproduction; 2004 Apr; 127(4):483-9. PubMed ID: 15047939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5.
    Kitajima Y; Endo T; Nagasawa K; Manase K; Honnma H; Baba T; Hayashi T; Chiba H; Sawada N; Saito T
    Endocrinology; 2006 Feb; 147(2):694-9. PubMed ID: 16269461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiology and pathology of ovarian hyperstimulation syndrome.
    Gómez R; Soares SR; Busso C; Garcia-Velasco JA; Simón C; Pellicer A
    Semin Reprod Med; 2010 Nov; 28(6):448-57. PubMed ID: 21082502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model.
    Akman L; Sahin G; Erbas O; Aktug H; Akdogan A; Goker EN; Taskiran D; Tavmergen E
    Gynecol Endocrinol; 2015 May; 31(5):369-73. PubMed ID: 25599748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immature rat ovaries become revascularized rapidly after autotransplantation and show a gonadotropin-dependent increase in angiogenic factor gene expression.
    Dissen GA; Lara HE; Fahrenbach WH; Costa ME; Ojeda SR
    Endocrinology; 1994 Mar; 134(3):1146-54. PubMed ID: 8119153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome.
    Tong XM; Zhang SY; Song T; Xu WH; Lin XN; Shu J; Liu L
    Chin Med J (Engl); 2008 Dec; 121(23):2434-9. PubMed ID: 19102964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists.
    Ferrero H; García-Pascual CM; Gaytán M; Morales C; Simón C; Gaytán F; Pellicer A; Gómez R
    Fertil Steril; 2014 Nov; 102(5):1468-1476.e1. PubMed ID: 25217874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.